{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:14:16Z","timestamp":1773058456430,"version":"3.50.1"},"reference-count":41,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1092852921000043_sec2\"><jats:title>Background<\/jats:title><jats:p>Differences in psychiatric background and dose\u2013response to asenapine in patients with schizophrenia were examined based on efficacy and safety, using data obtained in a double-blind, placebo-controlled trial.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000043_sec3\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Patients with schizophrenia were classified into three clusters by a cluster analysis based on the Positive and Negative Symptom Scale (PANSS) subscores at baseline, using the data from a 6-week, double-blind, placebo-controlled trial. PANSS Marder factor scores were calculated for each cluster. The efficacy of 10 or 20\u00a0mg\/day of asenapine on PANSS score was used as the primary endpoint, with the incidence of adverse events evaluated as the secondary endpoint.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000043_sec4\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>A total of 529 asenapine-treated patients were classified into 3 clusters: Cluster-P with the higher scores in positive symptoms, disorganized thoughts, and hostility\/excitement, Cluster-N with higher scores in negative symptoms, and Cluster-L with overall lower scores. In Cluster-N and Cluster-L, both 10 and 20\u00a0mg\/day groups showed significant improvement in PANSS scores, while only the 20\u00a0mg\/day group showed a significant difference in Cluster-P. Cluster-N and Cluster-L had differences in the incidence of adverse events, but this was not seen in Cluster-P.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000043_sec5\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>The efficacy and safety of asenapine 10 and 20\u00a0mg\/day differed between the 3 clusters of patients. This suggests that background information regarding baseline psychiatric symptoms may affect the therapeutic response in patients with schizophrenia.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852921000043","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T06:11:59Z","timestamp":1611036719000},"page":"369-377","source":"Crossref","is-referenced-by-count":8,"title":["Divergence of dose\u2013response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study"],"prefix":"10.1017","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-4033","authenticated-orcid":false,"given":"Yoshiteru","family":"Takekita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotaka","family":"Sunada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuatsu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Funatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyo","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Koshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"S1092852921000043_r20","volume-title":"DIEPSS: A Second-Generation Rating Scale for Antipsychotic-Induced Extrapyramidal Symptoms: Drug-Induced Extrapyramidal Symptoms Scale","author":"Inada","year":"2009"},{"key":"S1092852921000043_r11","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050277"},{"key":"S1092852921000043_r28","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.975"},{"key":"S1092852921000043_r36","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12103"},{"key":"S1092852921000043_r24","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp149"},{"key":"S1092852921000043_r35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0214"},{"key":"S1092852921000043_r16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010034"},{"key":"S1092852921000043_r22","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082944"},{"key":"S1092852921000043_r8","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2019.1613965"},{"key":"S1092852921000043_r39","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0502-5"},{"key":"S1092852921000043_r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.08.031"},{"key":"S1092852921000043_r2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"S1092852921000043_r21","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9247-4"},{"key":"S1092852921000043_r33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.2.255"},{"key":"S1092852921000043_r1","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Leheman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"S1092852921000043_r38","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.3.2.201"},{"key":"S1092852921000043_r4","unstructured":"4. NICE. Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178. London, UK: National Institute for Health and Care Excellence; 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK248060\/pdf\/Bookshelf_NBK248060.pdf"},{"key":"S1092852921000043_r6","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10490"},{"key":"S1092852921000043_r7","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby060"},{"key":"S1092852921000043_r27","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170200675X"},{"key":"S1092852921000043_r3","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"S1092852921000043_r34","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)01026-X"},{"key":"S1092852921000043_r9","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa063"},{"key":"S1092852921000043_r10","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200004000-00009"},{"key":"S1092852921000043_r19","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon"},{"key":"S1092852921000043_r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.07.055"},{"key":"S1092852921000043_r17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.138578"},{"key":"S1092852921000043_r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2013.04.007"},{"key":"S1092852921000043_r26","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12030"},{"key":"S1092852921000043_r32","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.172"},{"key":"S1092852921000043_r23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706780"},{"key":"S1092852921000043_r18","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/11.3.471"},{"key":"S1092852921000043_r37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00702"},{"key":"S1092852921000043_r41","first-page":"162","article-title":"Positive and negative symptoms in schizophrenia relate to distinct oscillatory signatures of sensory gating","volume":"10","author":"Keil","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"S1092852921000043_r12","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31817e63a5"},{"key":"S1092852921000043_r25","unstructured":"25. WHO. Collaborating centre for drug statistics methodology 2009. http:\/\/www.whocc.no\/atcddd\/. Accessed June 10, 2020."},{"key":"S1092852921000043_r13","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.137.245"},{"key":"S1092852921000043_r31","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-017-0274-9"},{"key":"S1092852921000043_r29","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.10.1785"},{"key":"S1092852921000043_r5","first-page":"CD011883","article-title":"Increasing antipsychotic dose for nonresponse in schizophrenia","volume":"5","author":"Samara","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852921000043_r14","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4295-9"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852921000043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:23:02Z","timestamp":1653312182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852921000043\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1092852921000043"],"URL":"https:\/\/doi.org\/10.1017\/s1092852921000043","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]}}}